FBR Capital Initiates Coverage on Achillion Pharmaceuticals(NASDAQ:ACHN). The shares have been rated Outperform. The rating by FBR Capital was issued on Sep 15, 2016.
In a different note, Chardan Capital said it Initiates Coverage on Achillion Pharmaceuticals, according to a research note issued on Jul 14, 2016. The shares have been rated ‘Sell’ by the firm. On Jul 7, 2016, JMP Securities said it Upgrades its rating on Achillion Pharmaceuticals. The shares have been rated ‘Market Outperform’ by the firm.
Achillion Pharmaceuticals (ACHN) made into the market gainers list on Tuesdays trading session with the shares advancing 1.92% or 0.15 points. Due to strong positive momentum, the stock ended at $7.96, which is also near the day’s high of $8. The stock began the session at $7.9 and the volume stood at 24,33,592 shares. The 52-week high of the shares is $10.95 and the 52 week low is $5.57. The company has a current market capitalization of $1,088 M and it has 13,66,80,890 shares in outstanding.
Achillion Pharmaceuticals(ACHN) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.14. Analysts had estimated an EPS of $-0.15.
Several Insider Transactions has been reported to the SEC. On Dec 30, 2015, Mary Kay Fenton (Chief Financial Officer) sold 43,500 shares at $10.08 per share price.Also, On Dec 30, 2015, David Apelian (Chief Medical Officer) sold 10,000 shares at $10.50 per share price.On Nov 12, 2015, Nicole Vitullo (director) sold 550,000 shares at $10.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.